Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Zolpidem is a non-benzodiazepine sedative-hypnotic indicated for the short-term treatment of insomnia. It works by enhancing GABA activity in the brain to facilitate sleep onset and maintenance.
Name
Zolpidem
Raw Name
ZOLPIDEM TARTRATE
Category
Other
Salt Form
Tartrate
Drug Count
5
Variant Count
155
Last Verified
February 17, 2026
RxCUI
854880, 854894, 854873, 854876, 836641, 836645, 836647, 836649, 1232194, 1232202, 2637353, 854875, 854878, 854882, 854896
UNII
WY6W63843K
About Zolpidem
Zolpidem is a non-benzodiazepine sedative-hypnotic indicated for the short-term treatment of insomnia. It works by enhancing GABA activity in the brain to facilitate sleep onset and maintenance.
Detailed information about Zolpidem
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Zolpidem.
Zolpidem was first approved by the U.S. Food and Drug Administration (FDA) in 1992 under the brand name Ambien. Since its introduction, it has become one of the most widely prescribed medications for the short-term management of insomnia (difficulty falling or staying asleep). It is categorized as a Schedule IV controlled substance in the United States, indicating a potential for misuse and dependence, though lower than that of Schedule II or III substances. Healthcare providers typically prescribe zolpidem for patients who experience significant distress or functional impairment due to sleep disturbances.
To understand how zolpidem works, one must understand the role of Gamma-Aminobutyric Acid (GABA), the primary inhibitory neurotransmitter in the human central nervous system. GABA acts as a 'brake' on the brain's activity, slowing down neuronal firing to induce relaxation and sleep. Zolpidem acts as a positive allosteric modulator of GABA-A receptors. This means it does not replace GABA but rather enhances the effect of naturally occurring GABA at the receptor site.
When zolpidem binds to the alpha-1 subunit of the GABA-A receptor complex, it causes a structural change in the receptor that allows chloride ions to flow more freely into the neuron. This influx of negatively charged ions hyperpolarizes the cell, making it less likely to fire an action potential (electrical signal). The result is a rapid induction of sedation. Because of its high selectivity for the alpha-1 subunit, zolpidem is particularly effective at inducing sleep without significantly altering the normal sleep architecture (the stages of sleep), although some reduction in REM (Rapid Eye Movement) sleep has been observed at higher doses.
Zolpidem is rapidly absorbed from the gastrointestinal tract following oral administration. The immediate-release (IR) formulation typically reaches peak plasma concentrations (Tmax) within 1.5 to 2.5 hours. The absolute bioavailability is approximately 70%, though this can be significantly reduced by the presence of food in the stomach. Clinical studies have shown that taking zolpidem with or immediately after a meal can delay the time to peak concentration and reduce the overall absorption, potentially leading to a delayed onset of sleep.
Zolpidem is highly protein-bound (approximately 92.5%), primarily to albumin. It is lipophilic (fat-soluble), which allows it to cross the blood-brain barrier rapidly, accounting for its quick onset of action. Despite its high protein binding, it does not typically displace other highly bound drugs like warfarin in clinical settings.
Metabolism occurs primarily in the liver through the cytochrome P450 (CYP) enzyme system. The primary enzyme involved is CYP3A4, with minor contributions from CYP1A2 and CYP2D6. Zolpidem is converted into three inactive metabolites, meaning the drug's effects are terminated as soon as it is processed by the liver. There are no known active metabolites that contribute to its sedative effect.
The elimination half-life of zolpidem is relatively short, averaging about 2.5 to 3 hours in healthy adults. This short half-life is advantageous for minimizing 'morning-after' grogginess, provided the patient gets a full 7 to 8 hours of sleep. Elimination occurs primarily through renal excretion (approximately 56%) and fecal excretion (approximately 37%).
Zolpidem is FDA-approved for the following indications:
Off-label uses, though less common and requiring strict medical supervision, have included the management of certain neurological conditions such as persistent vegetative states or Parkinson's disease, where paradoxical arousal has been observed in rare case reports. However, these uses are not standard clinical practice.
Zolpidem is available in several delivery systems to suit different patient needs:
> Important: Only your healthcare provider can determine if Zolpidem is right for your specific condition. A thorough evaluation of sleep hygiene and underlying causes of insomnia should be conducted before initiating pharmacotherapy.
The dosage of zolpidem must be individualized based on the patient's clinical response, age, and gender. In 2013, the FDA issued a safety communication requiring manufacturers to lower the recommended dose for women, as data showed that women clear zolpidem from their bodies more slowly than men, leading to higher morning-after blood levels and increased risk of impaired driving.
Zolpidem is NOT approved for use in pediatric patients. Clinical trials in children with Attention-Deficit/Hyperactivity Disorder (ADHD) associated insomnia failed to demonstrate efficacy and showed an increased incidence of hallucinations and other psychiatric adverse events compared to placebo. Healthcare providers generally avoid prescribing zolpidem to individuals under the age of 18.
No dosage adjustment is typically required in patients with renal impairment, as the drug is metabolized into inactive compounds before excretion. However, these patients should be monitored closely for signs of excessive sedation.
Because zolpidem is primarily metabolized by the liver, patients with hepatic impairment (liver dysfunction) experience significantly increased plasma concentrations and a prolonged half-life. The recommended starting dose in patients with mild to moderate hepatic impairment is 5 mg (IR) or 6.25 mg (ER) once daily at bedtime. It should be avoided in patients with severe hepatic impairment as it may precipitate encephalopathy (brain dysfunction due to liver failure).
Elderly patients are more sensitive to the effects of zolpidem and are at a higher risk of falls and cognitive impairment. The recommended dose for patients over the age of 65 is 5 mg (IR) or 6.25 mg (ER) once daily immediately before bedtime.
For optimal safety and efficacy, zolpidem should be taken exactly as prescribed:
If you miss a dose of zolpidem, do not take it unless you have enough time for a full night's sleep (7-8 hours). Never 'double up' on doses to make up for a missed one. If you wake up in the middle of the night and realize you missed your bedtime dose, skip it and resume your normal schedule the following night.
Signs of a zolpidem overdose may include extreme drowsiness, confusion, shallow breathing, limp muscles, fainting, or coma. If an overdose is suspected, contact emergency services (911) or a poison control center immediately. In a clinical setting, Flumazenil may be used as an antidote, though it carries a risk of inducing seizures, particularly in chronic users.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can lead to withdrawal symptoms.
Common side effects of zolpidem are typically dose-related and often subside as the body adjusts to the medication. These include:
> Warning: Stop taking Zolpidem and call your doctor immediately if you experience any of these serious adverse events.
While zolpidem is intended for short-term use (typically 7 to 10 days), long-term use can lead to several complications:
Zolpidem carries a prominent FDA Black Box Warning regarding Complex Sleep Behaviors. The warning states that serious injuries and deaths have occurred as a result of sleepwalking, sleep-driving, and engaging in other activities while not fully awake. If a patient experiences even one episode of complex sleep behavior, zolpidem must be discontinued immediately and permanently. These behaviors can occur at therapeutic doses, with or without the use of alcohol or other CNS depressants.
Report any unusual symptoms or behavioral changes to your healthcare provider immediately. Monitoring by a partner or caregiver is often recommended during the first few nights of treatment.
Zolpidem is a powerful sedative that requires careful medical supervision. It is not a permanent solution for insomnia and should be used as part of a comprehensive treatment plan that includes Cognitive Behavioral Therapy for Insomnia (CBT-I) and improved sleep hygiene. Patients must ensure they have a full 7 to 8 hours to devote to sleep before taking this medication to avoid morning-after impairment.
Complex sleep behaviors, including sleepwalking, sleep-driving, and engaging in other activities while not fully awake, may occur after taking zolpidem. Some of these events may result in serious injuries, including death. Discontinue zolpidem immediately if a patient experiences a complex sleep behavior. These events can occur after the first dose or at any time during treatment. Use of alcohol and other CNS depressants with zolpidem increases the risk of these behaviors.
Cases of severe angioedema (swelling of the deep layers of the skin) involving the tongue, glottis, or larynx have been reported. This can lead to airway obstruction and death. Patients who develop such reactions should never be rechallenged with zolpidem.
Like all sedative-hypnotics, zolpidem causes central nervous system (CNS) depression. This impairment can persist into the day following ingestion, even if the patient feels fully awake. The risk is higher if zolpidem is taken with less than 7-8 hours of sleep remaining, if a higher-than-recommended dose is taken, or if it is co-administered with other CNS depressants.
In patients with primary depressive disorders, zolpidem may worsen the condition. Suicidal 'ideation' (thoughts) and completed suicides have been reported in patients taking sedative-hypnotics. The least amount of drug feasible should be prescribed to patients with depression to prevent intentional overdose.
Zolpidem should be used with caution in patients with compromised respiratory function, such as those with Sleep Apnea or Chronic Obstructive Pulmonary Disease (COPD), as it may further suppress the drive to breathe.
Healthcare providers may require periodic monitoring for patients on long-term or repeated zolpidem therapy:
Do not drive, operate heavy machinery, or engage in hazardous activities the day after taking zolpidem until you are certain you are fully awake and alert. The FDA warns that zolpidem blood levels may remain high enough the next morning to impair driving, even if you do not feel drowsy.
Alcohol must be strictly avoided while taking zolpidem. Alcohol has a synergistic effect with zolpidem, meaning it significantly increases the sedative effects and the risk of dangerous respiratory depression and complex sleep behaviors.
If zolpidem has been taken for more than a few weeks, it should not be stopped abruptly. Sudden discontinuation can lead to withdrawal symptoms, including shakiness, sweating, stomach cramps, vomiting, and in rare cases, seizures. A gradual taper under medical supervision is the safest way to discontinue the drug.
> Important: Discuss all your medical conditions, especially any history of substance abuse or mental health issues, with your healthcare provider before starting Zolpidem.
Sodium Oxybate (Xyrem): Using zolpidem with sodium oxybate is generally contraindicated. Both drugs are potent CNS depressants, and their combined use can lead to severe respiratory distress, coma, and death. This combination significantly increases the risk of 'obtundation' (reduced level of consciousness).
The co-administration of zolpidem with other CNS depressants—including opioids (e.g., oxycodone, morphine), benzodiazepines (e.g., alprazolam, lorazepam), sedating antidepressants, and certain antihistamines—can lead to additive effects. This increases the risk of profound sedation, respiratory depression, and psychomotor impairment. If these must be used together, the dose of one or both agents should be reduced.
Since zolpidem is metabolized by the CYP3A4 enzyme, drugs that affect this enzyme will alter zolpidem levels:
SSRIs (Selective Serotonin Reuptake Inhibitors): Drugs like sertraline (Zoloft) or fluoxetine (Prozac) may interact with zolpidem. In some clinical trials, the combination of zolpidem and sertraline resulted in increased sleepiness and a few cases of hallucinations.
High-Fat Meals: Consuming a high-fat meal immediately before taking zolpidem can significantly delay the absorption of the drug. This results in a longer time to reach peak plasma concentration (Tmax) and a lower peak concentration (Cmax), which may prevent the drug from working quickly enough to help you fall asleep.
Alcohol: As previously mentioned, alcohol is the most dangerous 'food' interaction. It enhances the CNS depressant effects of zolpidem and increases the risk of parasomnias (unusual sleep behaviors).
Zolpidem does not typically interfere with standard clinical laboratory tests. However, it may show up on specialized toxicology screens for 'Z-drugs.' It does not usually cause a false positive for benzodiazepines on standard urine drug screens, though cross-reactivity depends on the specific assay used.
For each major interaction, the primary management strategy is 'start low and go slow.' If a patient is already on a CYP3A4 inhibitor, the healthcare provider may start with the lowest possible dose of zolpidem (e.g., 5 mg for men). If a patient requires an opioid for pain management, the provider must warn the patient about the extreme risks of sedation and may choose a non-sedating alternative for sleep.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter sleep aids.
There are several conditions where the use of zolpidem is strictly prohibited due to the risk of life-threatening adverse events:
Relative contraindications require a careful risk-benefit analysis by a healthcare professional:
While zolpidem is chemically distinct from benzodiazepines, patients who have had unusual psychiatric reactions to other 'Z-drugs' (zaleplon, eszopiclone) may be at an increased risk of similar reactions with zolpidem. There is no known cross-allergenicity between zolpidem and benzodiazepines, but caution is always warranted when switching between classes of sedatives.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of breathing problems or liver disease, before prescribing Zolpidem.
Zolpidem is currently classified under the newer FDA Pregnancy and Lactation Labeling Rule (PLLR), which replaced the old Category C system. Data on zolpidem use in pregnant women are limited. However, some observational studies have suggested a possible link between sedative use in the third trimester and an increased risk of neonatal respiratory depression and 'floppy infant syndrome' (hypotonia).
There is no clear evidence that zolpidem causes major birth defects (teratogenicity), but it does cross the placenta. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. If used near the time of delivery, the newborn should be monitored for signs of excess sedation or withdrawal symptoms.
Zolpidem is excreted into human breast milk in small amounts. Studies have shown that the milk-to-plasma ratio is low, and the total amount of drug an infant would receive is estimated to be less than 0.02% of the mother's weight-adjusted dose. While this is considered low risk, a nursing infant should be monitored for excessive sleepiness, poor feeding, or limpness. Some experts recommend waiting at least 3 to 4 hours after taking a dose before breastfeeding to minimize exposure.
As noted previously, zolpidem is not approved for use in children under 18. In a 2007 study of children with ADHD-related insomnia, zolpidem failed to improve sleep compared to placebo and was associated with a high rate of hallucinations and dizziness. The safety and efficacy in this population have not been established.
Patients over the age of 65 are significantly more sensitive to the effects of zolpidem. According to the Beers Criteria (a guideline for safe medication use in the elderly), zolpidem is listed as a potentially inappropriate medication because it increases the risk of falls, hip fractures, and motor vehicle accidents. If it must be used, the lowest possible dose (5 mg) should be prescribed, and the patient should be monitored for cognitive changes or 'sundowning' (increased confusion in the evening).
In patients with end-stage renal disease or those undergoing hemodialysis, the pharmacokinetics of zolpidem are not significantly altered. No specific dose adjustment is required based solely on renal function, although general caution in medically fragile patients is advised.
In patients with hepatic cirrhosis, the peak plasma concentration (Cmax) and area under the curve (AUC) of zolpidem are significantly increased, and the half-life is prolonged to approximately 10 hours (compared to 2.5 hours in healthy adults). Dosage must be reduced to 5 mg (IR) or 6.25 mg (ER) in patients with mild to moderate hepatic impairment. It is contraindicated in severe hepatic impairment.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the medication remains safe and effective.
Zolpidem is a non-benzodiazepine hypnotic of the imidazopyridine class. Its primary molecular target is the GABA-A receptor complex, specifically the alpha-1 (α1) subunit. The GABA-A receptor is a ligand-gated chloride channel. When zolpidem binds to the benzodiazepine site (specifically the BZ1 or ω1 site) located between the alpha-1 and gamma-2 subunits, it increases the receptor's affinity for GABA. This leads to an increased frequency of chloride channel opening, resulting in neuronal hyperpolarization and a rapid sedative effect. Its selectivity for the α1 subunit explains why it lacks the significant muscle-relaxant or anti-seizure properties of non-selective benzodiazepines which also bind to α2, α3, and α5 subunits.
The pharmacodynamic effect of zolpidem is characterized by a rapid onset of action (usually within 15–30 minutes) and a relatively short duration of effect. It primarily affects sleep latency (the time it takes to fall asleep). In extended-release forms, it also affects sleep maintenance. Tolerance to the hypnotic effects of zolpidem typically does not develop over a short course (up to 4 weeks), but long-term use may lead to reduced efficacy and the need for higher doses.
| Parameter | Value |
|---|---|
| Bioavailability | ~70% |
| Protein Binding | 92.5% |
| Half-life | 2.5 - 3.0 hours |
| Tmax | 1.6 hours (IR); 1.5 hours (ER) |
| Metabolism | Hepatic (CYP3A4 primary) |
| Excretion | Renal 56%, Fecal 37% |
Zolpidem is classified as a Non-Benzodiazepine Sedative-Hypnotic, often referred to as a 'Z-drug.' Other medications in this therapeutic class include Zaleplon (Sonata) and Eszopiclone (Lunesta). While they share a similar mechanism of action to benzodiazepines (like Temazepam), their chemical structures are distinct, and they are generally preferred for the treatment of insomnia due to their shorter half-lives and lower risk of disrupting sleep architecture.
Medications containing this ingredient
Common questions about Zolpidem
Zolpidem is primarily used for the short-term treatment of insomnia, a condition where individuals have trouble falling or staying asleep. It is specifically indicated for patients who experience significant distress or impairment in their daily lives due to lack of sleep. The immediate-release version is best for those who struggle to fall asleep, while the extended-release version helps those who wake up frequently during the night. Healthcare providers typically prescribe it for a duration of 7 to 10 days to avoid dependence. It should always be used in conjunction with good sleep hygiene practices.
The most frequently reported side effects of zolpidem include daytime drowsiness, dizziness, lightheadedness, and a 'drugged' feeling the next morning. Some patients also experience headaches, nausea, or diarrhea shortly after taking the medication. Because it is a sedative, it can impair your coordination and increase the risk of falls, especially in older adults. Most of these side effects are dose-dependent and may improve if the dose is lowered by a doctor. If these symptoms persist or become bothersome, you should consult your healthcare provider for a clinical review.
No, you should never consume alcohol while taking zolpidem. Alcohol and zolpidem are both central nervous system depressants, and combining them can lead to dangerous levels of sedation and respiratory depression. This combination significantly increases the risk of 'complex sleep behaviors' like sleep-walking or sleep-driving, which can be fatal. Even small amounts of alcohol can interfere with how your body processes the medication, leading to unpredictable and hazardous side effects. Always wait until the medication is completely out of your system before consuming alcohol.
Zolpidem should only be used during pregnancy if the potential benefits outweigh the possible risks to the developing fetus, as determined by a doctor. While there is no definitive evidence that it causes birth defects, some studies have linked its use in the late third trimester to respiratory problems and muscle weakness in newborns. It does cross the placenta and can affect the baby's central nervous system. Pregnant women struggling with insomnia should first explore non-pharmacological treatments like Cognitive Behavioral Therapy. Always inform your obstetrician if you are taking or considering zolpidem while pregnant.
Zolpidem is designed to work very quickly, typically inducing sleepiness within 15 to 30 minutes of administration. Because of this rapid onset, it is essential to take the medication only when you are already in bed or ready to go to sleep immediately. Taking it while you are still active can lead to memory loss or accidental falls. To ensure the fastest onset, you should take zolpidem on an empty stomach, as a heavy or high-fat meal can significantly delay its absorption. If it does not help you fall asleep within an hour, do not take a second dose.
If you have been taking zolpidem for more than a week or two, you should not stop taking it suddenly without consulting your doctor. Abrupt discontinuation can lead to 'rebound insomnia,' where your sleep problems return and may be worse than before you started the drug. It can also cause withdrawal symptoms such as anxiety, shakiness, sweating, and stomach cramps. Your healthcare provider will usually recommend a gradual tapering of the dose to allow your brain to readjust. This process helps minimize discomfort and ensures a safer transition off the medication.
If you miss your dose of zolpidem at bedtime, you should only take it if you still have enough time for a full 7 to 8 hours of sleep before you need to be active again. If you wake up in the middle of the night and realize you forgot your dose, it is usually best to skip it to avoid morning-after grogginess and impairment. Never take two doses at once to make up for a missed one. Simply resume your regular schedule the following night. If you frequently forget your medication, consider setting a reminder or discussing alternative treatments with your doctor.
Weight gain is not a direct or common side effect of zolpidem itself. However, a rare but serious side effect known as 'sleep-eating' can lead to unintended weight gain. During these episodes, patients may prepare and eat entire meals while asleep and have no memory of doing so the next day. If you notice unexplained weight gain or find evidence of nighttime eating (like crumbs or empty wrappers in bed), notify your doctor immediately. This is considered a complex sleep behavior and usually requires the immediate discontinuation of the medication.
Zolpidem can interact with many other drugs, particularly those that also cause drowsiness, such as opioids, benzodiazepines, and certain antidepressants. It also interacts with medications that affect liver enzymes, like the antibiotic rifampin or the antifungal ketoconazole. These interactions can either make zolpidem less effective or dangerously increase its concentration in your blood. It is vital to provide your doctor and pharmacist with a complete list of all medications, herbs, and supplements you are taking. They can check for potential interactions and adjust your treatment plan to ensure your safety.
Yes, zolpidem tartrate is widely available as a generic medication in both immediate-release and extended-release formulations. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug (Ambien). They are typically much more affordable than the brand-name versions and are covered by most insurance plans. When you receive a refill, the tablets may look different in color or shape depending on the manufacturer, but the clinical effect should remain the same. If you have concerns about a generic switch, speak with your pharmacist.